Polaryx Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-8.99	-30.36	-3.78
Stock-Based Compensation	4.73	2.4	3.24
Other Adjustments	-	26	-
Changes in Accounts Payable	0.4	-0.4	-0.05
Changes in Accrued Expenses	-0.04	-	-0
Changes in Other Operating Activities	-0.04	-0.22	0.43
Operating Cash Flow	-3.94	-2.57	-0.17
Short-Term Debt Issued	-	0.07	0.13
Short-Term Debt Repaid	-	-0.19	-
Net Short-Term Debt Issued (Repaid)	-	-0.13	0.13
Issuance of Common Stock	4.49	7.32	-
Net Common Stock Issued (Repurchased)	4.49	7.32	-
Other Financing Activities	-0.03	-	-
Financing Cash Flow	4.47	7.19	0.13
Net Cash Flow	0.52	4.62	-0.05

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q